North America Cancer Gene Therapy Market Size & Outlook

The cancer gene therapy market in North America is expected to reach a projected revenue of US$ 5,146.9 million by 2030. A compound annual growth rate of 20.6% is expected of North America cancer gene therapy market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,704.3
Forecast, 2030 (US$M)
$5,146.9
CAGR, 2025 - 2030
20.6%
Report Coverage
North America

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America cancer gene therapy market, 2018-2030 (US$M)

North America cancer gene therapy market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America cancer gene therapy market highlights

  • The North America cancer gene therapy market generated a revenue of USD 1,704.3 million in 2024.
  • The market is expected to grow at a CAGR of 20.2% from 2025 to 2030.
  • In terms of segment, oncolytic virotherapy was the largest revenue generating therapy in 2024.
  • Oncolytic Virotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.


North America data book summary

Market revenue in 2024USD 1,704.3 million
Market revenue in 2030USD 5,146.9 million
Growth rate20.2% (CAGR from 2025 to 2030)
Largest segmentOncolytic virotherapy
Fastest growing segmentOncolytic Virotherapy
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationOncolytic Virotherapy
Key market players worldwideAbeona Therapeutics Inc, Asklepios, Bluebird bio Inc, Celgene, Avidity Biosciences Inc Ordinary Shares, GlaxoSmithKline, Genelux Corp, Gen Digital Inc, Protagonist Therapeutics Inc, Merck KGaA, Onconetix Inc


Other key industry trends

  • In terms of revenue, North America region accounted for 37.8% of the global cancer gene therapy market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • North America is the fastest growing regional market and is projected to reach USD 5,146.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer Gene Therapy Market Scope

Cancer gene therapy market segmentation & scope
Oncolytic Virotherapy
Gene Induced Immunotherapy
Gene Transfer
End Use
Research Institutes
Biopharmaceutical Companies
Diagnostic Centres
Others

Cancer Gene Therapy Market Companies

Name Profile # Employees HQ Website
Avidity Biosciences Inc Ordinary Shares View profile 253 10578 Science Center Drive, Suite 125, San Diego, CA, United States, 92121 https://www.aviditybiosciences.com
Abeona Therapeutics Inc View profile 84 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, United States, 44103 https://www.abeonatherapeutics.com
Genelux Corp View profile 23 2625 Townsgate Road, Suite 230, Westlake Village, CA, United States, 91361 https://www.genelux.com
Onconetix Inc View profile 12 201 East Fifth Street, Suite 1900, Cincinnati, OH, United States, 45202 https://www.onconetix.com
Asklepios View profile 10001+ Hamburg, Hamburg, Germany, Europe https://www.asklepios.com/proresearch/
GlaxoSmithKline View profile 10001+ London, England, United Kingdom, Europe http://www.gsk.com
Celgene View profile 10001+ Summit, New Jersey, United States, North America https://www.bms.com
Bluebird bio Inc View profile 323 455 Grand Union Boulevard, Somerville, MA, United States, 02145 https://www.bluebirdbio.com
Gen Digital Inc View profile 3400 60 E. Rio Salado Parkway, Suite 1000, Tempe, AZ, United States, 85281 https://www.gendigital.com
Protagonist Therapeutics Inc View profile 124 7707 Gateway Boulevard, Suite 140, Newark, CA, United States, 94560 https://www.protagonist-inc.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

North America cancer gene therapy market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer gene therapy market will help companies and investors design strategic landscapes.


Oncolytic virotherapy was the largest segment with a revenue share of 100% in 2024. Horizon Databook has segmented the North America cancer gene therapy market based on oncolytic virotherapy covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to North America cancer gene therapy market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America cancer gene therapy market databook

  • Our clientele includes a mix of cancer gene therapy market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America cancer gene therapy market , including forecasts for subscribers. This continent databook contains high-level insights into North America cancer gene therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online